GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings.Key metrics for WGS include test volume growth and reimbursement rates, with management targeting a 30% annual volume increase and improving price realization.Consensus-beating revenue is likely if test volume growth accelerates and pricing im...

Cidara’s CD388 is a novel flu prophylactic designed for universal prevention of seasonal and pandemic influenza through a single dose, with the potential to be the new standard of care.Phase 2 data showed efficacy of 78% for the highest dose, well ahead of traditional vaccines.Accelerated Phase 3 enrollment, with interim analysis in March 2026 and data readout expected around...